Literature DB >> 12074461

Clinical experience with intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of rectal balloon for prostate immobilization.

Bin S Teh1, Shiao Y Woo, Wei-Yuan Mai, John E Mcgary, L Steven Carpenter, Hsin H Lu, J Kam Chiu, Maria T Vlachaki, Walter H Grant, E Brian Butler.   

Abstract

The implementation of intensity-modulated radiation therapy (IMRT) is the result of advances in imaging, radiotherapy planning technologies, and computer-controlled linear accelerators. IMRT allows both conformal treatment of tumors and conformal avoidance of the surrounding normal structures. The first patient treated with Peacock IMRT at Baylor College of Medicine took place in March 1994. To date, more than 1500 patients have been treated with IMRT; more than 700 patients were treated for prostate cancer. Our experience in treating prostate cancer with IMRT was reviewed. Patient and prostate motions are important issues to address in delivering IMRT. The Vac-Lok bag-and-box system, as well as rectal balloon for immobilization of patient and prostate gland, respectively, are employed. Treatment planning also plays a very important role. IMRT as a boost after conventional external beam radiotherapy is not our treatment strategy. To derive maximal benefits with this new technology, all patients received full course IMRT. Three separate groups of patients receiving (1) primary IMRT, (2) combined radioactive seed implant and IMRT, and (3) post-prostatectomy IMRT were addressed. Overall, toxicity profiles in these patients were very favorable. IMRT has the potential to improve treatment outcome with dose escalation while minimizing treatment-related toxicity.

Entities:  

Mesh:

Year:  2002        PMID: 12074461     DOI: 10.1016/s0958-3947(02)00092-4

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  6 in total

1.  Penile bulb sparing in prostate cancer radiotherapy : Dose analysis of an in-house MRI system to improve contouring.

Authors:  F Böckelmann; M Hammon; S Lettmaier; R Fietkau; C Bert; F Putz
Journal:  Strahlenther Onkol       Date:  2018-10-12       Impact factor: 3.621

2.  Intrafractional prostate motion during external beam radiotherapy monitored by a real-time target localization system.

Authors:  Xu Tong; Xiaoming Chen; Jinsheng Li; Qianqian Xu; Mu-Han Lin; Lili Chen; Robert A Price; Chang-Ming Ma
Journal:  J Appl Clin Med Phys       Date:  2015-03-08       Impact factor: 2.102

Review 3.  Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives.

Authors:  Nicholas A Serrano; Noah S Kalman; Mitchell S Anscher
Journal:  Cancer Manag Res       Date:  2017-07-28       Impact factor: 3.989

4.  Treatments of exceptionally large prostate cancer patients with low-energy intensity-modulated photons.

Authors:  Mei Sun; Lijun Ma
Journal:  J Appl Clin Med Phys       Date:  2006-11-28       Impact factor: 2.102

5.  Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer.

Authors:  Bin S Teh; Gary D Lewis; Weiyuan Mai; Ramiro Pino; Hiromichi Ishiyama; Edward Brian Butler
Journal:  Cancer Commun (Lond)       Date:  2018-04-17

6.  Towards real-time PGS range monitoring in proton therapy of prostate cancer.

Authors:  Paulo Magalhaes Martins; Hugo Freitas; Thomas Tessonnier; Benjamin Ackermann; Stephan Brons; Joao Seco
Journal:  Sci Rep       Date:  2021-07-28       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.